0001104659-22-007648.txt : 20220126 0001104659-22-007648.hdr.sgml : 20220126 20220126074705 ACCESSION NUMBER: 0001104659-22-007648 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220126 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220126 DATE AS OF CHANGE: 20220126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 22555712 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 tm224433d1_8k.htm FORM 8-K
0000001800 false Common Shares, Without Par Value ABT 0000001800 2022-01-26 2022-01-26 0000001800 us-gaap:CommonStockMember exch:XCHI 2022-01-26 2022-01-26 0000001800 us-gaap:CommonStockMember exch:XNYS 2022-01-26 2022-01-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
   

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

January 26, 2022

Date of Report (Date of earliest event reported)

 

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 

 

 

Illinois   1-2189   36-0698440
(State or other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)

 

 

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading
Symbol(s)

Name of Each Exchange

on Which Registered

Common Shares, Without Par Value ABT New York Stock Exchange
 Chicago Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

Item 2.02Results of Operations and Financial Condition

 

On January 26, 2022, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2021.

 

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results.  In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings from continuing operations excluding specified items.  These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction initiatives, certain litigation, certain regulatory costs, the acquisition of an R&D asset, the impairment of certain assets, the gain on the disposition of an equity method investment, tax benefits associated with specified items, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance.  Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance.  Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses.  Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.  

 

Item 9.01Financial Statements and Exhibits

 

  Exhibit No.   Exhibit

 

99.1  Press Release dated January 26, 2022 (furnished pursuant to Item 2.02).

 

104  Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBOTT LABORATORIES
     
     
Date: January 26, 2022 By: /s/ Robert E. Funck, Jr.
    Robert E. Funck, Jr.
    Executive Vice President, Finance and Chief Financial Officer

 

 

 EX-99.1 2 tm224433d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

News Release

 

 

Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast

 

-Fourth-quarter sales growth of 7.2 percent; organic sales growth of 7.7 percent
-Global COVID-19 testing-related sales of $2.3 billion in the fourth quarter
-Excluding COVID-19 testing-related sales, fourth-quarter sales growth of 9.6 percent and organic sales growth of 10.3 percent
-Full-year 2021 sales growth of 24.5 percent; organic sales growth of 22.9 percent
-Full-year 2021 GAAP diluted EPS from continuing operations growth of 58.2 percent; adjusted diluted EPS growth of 42.7 percent
-R&D pipeline continues to deliver a steady cadence of new products, including several in large, fast-growing markets

 

 

ABBOTT PARK, Ill., Jan. 26, 2022 — Abbott today announced financial results for the fourth quarter and full year ended Dec. 31, 2021, and issued its financial outlook for 2022.

·Fourth-quarter sales of $11.5 billion increased 7.2 percent on a reported basis and 7.7 percent on an organic basis, which excludes the impact of foreign exchange.
·Fourth-quarter GAAP diluted EPS was $1.11 and adjusted diluted EPS, which excludes specified items, was $1.32.
·Full-year 2021 GAAP diluted EPS from continuing operations was $3.94 and adjusted diluted EPS from continuing operations was $5.21, reflecting 42.7% growth versus the prior year.1
·Global COVID-19 testing-related sales were $2.3 billion in the fourth quarter and $7.7 billion for the full-year. Abbott has distributed more than 1.4 billion COVID-19 tests since the start of the pandemic.
·Abbott issues full-year 2022 guidance for diluted EPS from continuing operations on a GAAP basis of at least $3.43 and full-year adjusted diluted EPS from continuing operations of at least $4.70.
·Full-year 2022 guidance includes an initial COVID-19 testing-related sales forecast of $2.5 billion, which Abbott expects to occur early in the year and will update on a quarterly basis.
·Abbott's R&D pipeline continues to deliver a steady cadence of new products. Select 2021 highlights include U.S. Centers for Medicare & Medicaid Services expanded reimbursement for MitraClip®, U.S. launches of Amplatzer® Amulet®, NeuroSphere™ Virtual Clinic, and Portico® transcatheter aortic valve replacement (TAVR) system, along with the international launch of Navitor™ TAVR system.

 

"2021 was an outstanding year for Abbott," said Robert B. Ford, chairman and chief executive officer, Abbott. "We achieved more than 40 percent EPS growth, exceeding the baseline EPS guidance we set at the beginning of last year and, importantly, continued to advance our new product pipeline across the portfolio."

 

—more—

 

 

 

 

FOURTH-Quarter Business Overview

Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange.

 

Following are sales by business segment and commentary for the fourth quarter 2021:

 

Total Company

($ in millions)

 

               % Change vs. 4Q20 
   Sales 4Q21   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total *   4,855    6,613    11,468    15.6    1.7    7.2    15.6    2.7    7.7 
Nutrition   928    1,114    2,042    10.4    1.7    5.5    10.4    2.4    5.9 
Diagnostics   2,386    2,085    4,471    20.5    (11.8)   2.9    20.5    (11.1)   3.3 
Established Pharmaceuticals   --    1,203    1,203     n/a     4.9    4.9     n/a     5.8    5.8 
Medical Devices   1,538    2,211    3,749    12.3    17.1    15.1    12.3    18.6    15.9 

 

* Total Q4 2021 Abbott sales from continuing operations include Other Sales of approximately $3 million.

 

               % Change vs. 12M20 
   Sales 12M21   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total *   16,642    26,433    43,075    27.8    22.5    24.5    27.8    19.9    22.9 
Nutrition   3,556    4,738    8,294    8.4    8.5    8.5    8.4    7.1    7.7 
Diagnostics   7,129    8,515    15,644    49.3    41.2    44.8    49.3    37.4    42.7 
Established Pharmaceuticals   --    4,718    4,718     n/a     9.6    9.6     n/a     10.4    10.4 
Medical Devices   5,923    8,444    14,367    20.1    23.2    21.9    20.1    18.8    19.4 

 

* Total 12M 2021 Abbott sales from continuing operations include Other Sales of approximately $52 million.

 

n/a = Not Applicable.

 

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

 

Fourth-quarter 2021 worldwide sales of $11.5 billion increased 7.2 percent on a reported basis and 7.7 percent on an organic basis. Full-year 2021 worldwide sales increased 24.5 percent on a reported basis and 22.9 percent on an organic basis.

 

Worldwide sales, excluding COVID-19 testing-related sales,2 increased 9.6 percent on a reported basis and 10.3 percent on an organic basis in the fourth quarter, and 15.2 percent on a reported basis and 13.7 percent on an organic basis in the full year 2021.

 

Compared to pre-pandemic sales in 2019, worldwide sales, excluding COVID-19 testing-related sales,3 increased 10.0 percent on a reported basis and 10.8 percent on an organic basis in the fourth quarter.

 

2

 

 

Nutrition

($ in millions)

 

                % Change vs. 4Q20 
    Sales 4Q21   Reported   Organic 
    U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total    928    1,114    2,042    10.4    1.7    5.5    10.4    2.4    5.9 
Pediatric    570    469    1,039    14.5    (8.0)   3.1    14.5    (8.1)   3.1 
Adult    358    645    1,003    4.5    10.3    8.1    4.5    11.6    9.0 

 

                % Change vs. 12M20 
    Sales 12M21   Reported   Organic 
    U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total    3,556    4,738    8,294    8.4    8.5    8.5    8.4    7.1    7.7 
Pediatric    2,192    2,106    4,298    10.3    (1.5)   4.2    10.3    (3.2)   3.3 
Adult    1,364    2,632    3,996    5.6    18.1    13.5    5.6    17.0    12.8 

 

Worldwide Nutrition sales increased 5.5 percent on a reported basis and 5.9 percent on an organic basis in the fourth quarter.

 

In Adult Nutrition, strong performance of Ensure®, Abbott's market-leading complete and balanced nutrition brand, and Glucerna®, Abbott's market-leading diabetes nutrition brand, led to global sales growth of 8.1 percent on a reported basis and 9.0 percent on an organic basis.

 

Worldwide Pediatric Nutrition sales increased 3.1 percent on both a reported basis and organic basis. Strong performance of Abbott's market-leading oral hydration brand, Pedialyte®, and continued share growth in infant nutrition led to U.S. Pediatric Nutrition growth of 14.5 percent. In International Pediatric Nutrition, sales were unfavorably impacted primarily by challenging market conditions in China.

 

3

 

 

Diagnostics

($ in millions)

 

               % Change vs. 4Q20 
   Sales 4Q21   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   2,386    2,085    4,471    20.5    (11.8)   2.9    20.5    (11.1)   3.3 
Core Laboratory   300    1,048    1,348    (8.0)   5.2    1.9    (8.0)   6.2    2.7 
Molecular   135    210    345    (30.0)   (27.5)   (28.5)   (30.0)   (27.3)   (28.4)
Point of Care   95    40    135    5.3    3.7    4.8    5.3    3.9    4.9 
Rapid Diagnostics   1,856    787    2,643    35.3    (24.2)   9.6    35.3    (23.8)   9.8 

 

               % Change vs. 12M20 
   Sales 12M21   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   7,129    8,515    15,644    49.3    41.2    44.8    49.3    37.4    42.7 
Core Laboratory   1,145    3,983    5,128    (1.8)   20.4    14.6    (1.8)   17.4    12.4 
Molecular   566    861    1,427    (8.9)   5.4    (0.8)   (8.9)   1.7    (2.9)
Point of Care   384    152    536    4.3    2.8    3.9    4.3    0.3    3.2 
Rapid Diagnostics   5,034    3,519    8,553    92.2    100.2    95.4    92.2    95.0    93.3 

 

Worldwide Diagnostics sales increased 2.9 percent on a reported basis in the fourth quarter and increased 3.3 percent on an organic basis. Global COVID-19 testing-related sales were $2.3 billion in the fourth quarter, including combined sales of $2.1 billion from Abbott's BinaxNOW®, Panbio® and ID NOW® rapid testing platforms.

 

Excluding COVID-19 testing-related sales, worldwide Diagnostics sales increased 8.2 percent on a reported basis in the fourth quarter and 8.7 percent on an organic basis.4

 

In Molecular Diagnostics, fourth-quarter sales growth was negatively impacted by lower COVID-19 testing-related sales compared to the prior year. Excluding COVID-19 testing-related sales, worldwide Molecular Diagnostics sales increased 24.1 percent on a reported basis and 24.5 percent on an organic basis, including 34.6 percent in the U.S. and 20.7 percent internationally.5

 

In Rapid Diagnostics, fourth-quarter international sales growth was negatively impacted by lower COVID-19 testing-related sales compared to the prior year. Excluding COVID-19 testing-related sales, international Rapid Diagnostics sales increased 9.7 percent on a reported basis and 10.3 percent on an organic basis.6

 

4

 

 

Established Pharmaceuticals

($ in millions)

 

               % Change vs. 4Q20  
   Sales 4Q21   Reported  Organic 
   U.S.   Int'l   Total   U.S.  Int'l   Total   U.S.   Int'l   Total 
Total   --    1,203    1,203    n/a   4.9    4.9     n/a     5.8    5.8 

Key Emerging Markets

   --    868    868    n/a   4.1    4.1     n/a     5.2    5.2 
Other   --    335    335    n/a   6.8    6.8     n/a     7.5    7.5 

 

               % Change vs. 12M20  
   Sales 12M21   Reported  Organic 
   U.S.   Int'l   Total   U.S.  Int'l   Total   U.S.   Int'l   Total 
Total   --    4,718    4,718    n/a   9.6    9.6     n/a     10.4    10.4 
Key Emerging Markets   --    3,539    3,539    n/a   10.3    10.3     n/a     11.9    11.9 
Other   --    1,179    1,179    n/a   7.8    7.8     n/a     6.0    6.0 

 

Established Pharmaceuticals sales increased 4.9 percent on a reported basis in the fourth quarter and increased 5.8 percent on an organic basis.

 

Key Emerging Markets include India, Brazil, Russia and China along with several additional emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 4.1 percent on a reported basis in the quarter and increased 5.2 percent on an organic basis. Organic sales growth was led by strong growth across several geographies, including India, Russia and China.

 

Other sales increased 6.8 percent on a reported basis in the quarter and increased 7.5 percent on an organic basis.

 

5

 

 

Medical Devices

($ in millions)

 

               % Change vs. 4Q20 
   Sales 4Q21   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   1,538    2,211    3,749    12.3    17.1    15.1    12.3    18.6    15.9 
Rhythm Management   242    299    541    (2.7)   5.5    1.7    (2.7)   7.0    2.5 
Electrophysiology   198    306    504    7.2    15.4    12.0    7.2    17.8    13.5 
Heart Failure   171    68    239    25.4    30.8    26.9    25.4    33.2    27.6 
Vascular   231    447    678    3.0    18.0    12.4    3.0    19.2    13.2 
Structural Heart   193    226    419    25.4    13.6    18.7    25.4    15.7    19.9 
Neuromodulation   156    41    197    (9.0)   (2.2)   (7.7)   (9.0)   (1.1)   (7.5)
Diabetes Care   347    824    1,171    38.8    23.5    27.6    38.8    24.3    28.3 

 

               % Change vs. 12M20 
   Sales 12M21   Reported   Organic 
   U.S.   Int'l   Total   U.S.   Int'l   Total   U.S.   Int'l   Total 
Total   5,923    8,444    14,367    20.1    23.2    21.9    20.1    18.8    19.4 
Rhythm Management   1,018    1,180    2,198    12.7    16.8    14.8    12.7    12.7    12.7 
Electrophysiology   778    1,129    1,907    17.7    23.1    20.8    17.7    20.0    19.1 
Heart Failure   654    235    889    19.5    22.0    20.1    19.5    18.1    19.1 
Vascular   915    1,739    2,654    7.4    17.0    13.5    7.4    13.2    11.1 
Structural Heart   730    880    1,610    35.1    24.5    29.1    35.1    20.4    26.8 
Neuromodulation   616    165    781    9.3    19.2    11.3    9.3    14.3    10.3 
Diabetes Care   1,212    3,116    4,328    40.3    29.6    32.5    40.3    24.3    28.5 

 

Worldwide Medical Devices sales increased 15.1 percent on a reported basis in the fourth quarter and increased 15.9 percent on an organic basis. Strong growth in the quarter was driven by continued recovery from the COVID-19 pandemic and strong growth in Diabetes Care.

 

Compared to pre-pandemic sales in 2019, Medical Devices sales increased 17.0 percent on a reported basis and 15.8 percent on an organic basis in the fourth quarter, led by double-digit growth in Heart Failure, Structural Heart and Diabetes Care.7

 

In Diabetes Care, FreeStyle Libre® sales were $1.0 billion in the quarter, which represents sales growth of 35.4 percent on a reported basis and 36.0 percent on an organic basis.

 

Abbott continued to strengthen its Medical Devices portfolio with several pipeline advancements in 2021, including:

 

·U.S. Centers for Medicare & Medicaid Services expanded reimbursement coverage for Abbott's revolutionary MitraClip device.

·U.S. launch of NeuroSphere Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians and receive new treatment settings remotely as needed.

·U.S. FDA approval of Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation who are at risk of ischemic stroke.

·U.S. FDA approval of Portico with FlexNav® transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high risk for open-heart surgery.

·CE Mark for Navitor, Abbott's latest-generation TAVR system.

 

6

 

 

Abbott'S EARNINGS-PER-SHARE guidance

Abbott projects full-year 2022 diluted earnings per share from continuing operations under GAAP of at least $3.43. Abbott forecasts specified items for the full-year 2022 of $1.27 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $4.70 for the full-year 2022.

 

Abbott projects first-quarter 2022 diluted earnings per share from continuing operations under GAAP of at least $1.20. Abbott forecasts specified items for the first-quarter 2022 of $0.30 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $1.50 for the first quarter.

 

Abbott declares 392nd consecutive QUARTERLY DIVIDEND

On Dec. 10, 2021, the board of directors of Abbott declared the company's quarterly dividend of $0.47 per share. Abbott's cash dividend is payable Feb. 15, 2022 to shareholders of record at the close of business on Jan. 14, 2022.

 

Abbott has increased its dividend payout for 50 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

 

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

 

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

 

Abbott will live-webcast its fourth-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later that day.

 

7

 

 

— Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

 

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

 

 

Abbott Financial:

Scott Leinenweber, 224-668-0791

Michael Comilla, 224-668-1872

Laura Dauer, 224-667-2299

 

Abbott Media:

Scott Stoffel, 224-668-5201

Kate Dyer, 224-668-9965

  
 

 

1Full-year 2021 diluted EPS from continuing operations on a GAAP basis reflects 58.2 percent growth.

2In the fourth quarter of 2020, total worldwide sales were $10.701 billion, which included COVID-19 testing-related sales of $2.35 billion. In the fourth quarter of 2021, COVID-19 testing-related sales were $2.319 billion. Full-year 2020 worldwide sales were $34.608 billion, which included COVID-19 testing-related sales of $3.878 billion. Full-year 2021 COVID-19 testing-related sales were $7.679 billion.

3In the fourth quarter of 2019, total worldwide sales were $8.314 billion. In the fourth quarter of 2021, COVID-19 testing-related sales were $2.319 billion. Full-year 2019 worldwide sales were $31.904 billion. Full-year 2021 COVID-19 testing-related sales were $7.679 billion.

4In the fourth quarter of 2020, worldwide Diagnostic sales were $4.345 billion, which included total COVID-19 testing-related sales of $2.35 billion. In the fourth quarter of 2021, COVID-19 testing-related sales were $2.319 billion. Full-year 2020 worldwide Diagnostic sales were $10.805 billion, which included COVID-19 testing-related sales of $3.878 billion in Diagnostics. Full-year 2021 COVID-19 testing-related sales were $7.679 billion.

5In the fourth quarter of 2020, worldwide Molecular sales were $482 million, which included $192 million of U.S. sales and $290 million of international sales. U.S. and international Molecular COVID-19 testing-related sales in the fourth quarter of 2020 were $158 million and $201 million, respectively. In the fourth quarter of 2021, U.S. and international Molecular COVID-19 testing-related sales were $89 million and $103 million, respectively.

6In the fourth quarter of 2020, international Rapid Diagnostics sales were $1.039 billion, which included COVID-19 testing related sales of $847 million. In the fourth quarter of 2021, international Rapid Diagnostics COVID-19 testing related sales were $577 million.

7In the fourth quarter of 2019, Medical Devices sales were $3.204 billion.

 

8

 

 

Abbott Laboratories and Subsidiaries 

Condensed Consolidated Statement of Earnings 

Fourth Quarter Ended December 31, 2021 and 2020 

(in millions, except per share data) 

(unaudited)

 

    4Q21     4Q20     % Change 
Net Sales  $11,468   $10,701    7.2 
                
Cost of products sold, excluding amortization expense   4,766    4,493    6.1 
Amortization of intangible assets   514    508    1.3 
Research and development   762    698    9.1 
Selling, general, and administrative   3,048    2,570    18.6 
Total Operating Cost and Expenses   9,090    8,269    9.9 
                
Operating Earnings   2,378    2,432    (2.2) 
                
Interest expense, net   120    127    (5.7) 
Net foreign exchange (gain) loss   (6)   (5)   22.8 
Other (income) expense, net   (63)   (78)   (19.3) 
Earnings from Continuing Operations before taxes   2,327    2,388    (2.5) 
                
Tax expense on Earnings from Continuing Operations   338    230    47.21)
Earnings from Continuing Operations   1,989    2,158    (7.8) 
                
Earnings from Discontinued Operations, net of taxes   --    4    n/m 
                
Net Earnings  $1,989   $2,162    (8.0) 
                
Earnings from Continuing Operations, excluding               
Specified Items, as described below  $2,366   $2,612    (9.4)2)
                
Diluted Earnings per Common Share from:               
Continuing Operations  $1.11   $1.20    (7.5) 
Discontinued Operations   --    --    n/m 
Total  $1.11   $1.20    (7.5) 
                
Diluted Earnings per Common Share from Continuing               
Operations, excluding Specified Items, as described below  $1.32   $1.45    (9.0)2)
                
Average Number of Common Shares Outstanding               
Plus Dilutive Common Stock Options   1,782    1,789      

 

NOTES:

See tables on page 13 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

 

9

 

 

1)2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $40 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $45 million in excess tax benefits associated with share-based compensation.

 

2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $135 million of tax benefits related to the impairment of certain assets, approximately $25 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $10 million in excess tax benefits associated with share-based compensation.

 

2)2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $377 million, or $0.21 per share, for intangible amortization and other expenses primarily associated with restructuring actions and acquisitions, partially offset by a change in estimate to the restructuring actions recognized in the second quarter related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.

 

2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $454 million, or $0.25 per share, for intangible amortization and impairment expenses and other net expenses primarily associated with acquisitions and restructuring actions.

 

10

 

 

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Year Ended December 31, 2021 and 2020

(in millions, except per share data)

(unaudited)

 

    12M21     12M20    % Change    
Net Sales  $43,075   $34,608   24.5    
                  
Cost of products sold, excluding amortization expense   18,537    15,003   23.6    
Amortization of intangible assets   2,047    2,132   (4.0)    
Research and development   2,742    2,420   13.3    
Selling, general, and administrative   11,324    9,696   16.8    
Total Operating Cost and Expenses   34,650    29,251   18.5    
                  
Operating Earnings   8,425    5,357   57.3    
                  
Interest expense, net   490    500   (2.0)    
Net foreign exchange (gain) loss   1    (8)  n/m    
Other (income) expense, net   (277)   (103)  169.7    
Earnings from Continuing Operations before taxes   8,211    4,968   65.3    
                  
Tax expense on Earnings from Continuing Operations   1,140    497   129.4 1)  
Earnings from Continuing Operations   7,071    4,471   58.2    
                  
Earnings from Discontinued Operations, net of taxes   --    24   n/m    
                  
Net Earnings  $7,071   $4,495   57.3    
                  
Earnings from Continuing Operations, excluding                 
Specified Items, as described below  $9,367   $6,552   43.0 2)  
                  
Diluted Earnings per Common Share from:                 
Continuing Operations  $3.94   $2.49   58.2    
Discontinued Operations   --    0.01   n/m    
Total  $3.94   $2.50   57.6    
                  
Diluted Earnings per Common Share from Continuing                 
Operations, excluding Specified Items, as described below  $5.21   $3.65    42.7 2)  
                  
Average Number of Common Shares Outstanding                 
Plus Dilutive Common Stock Options   1,789    1,786        

 

NOTES:

See tables on page 14 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

 

11

 

 

1)2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $55 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $145 million in excess tax benefits associated with share-based compensation.

 

2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $170 million of tax benefits related to the impairment of certain assets, $140 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $100 million in excess tax benefits associated with share-based compensation.

 

2)2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.296 billion, or $1.27 per share, for intangible amortization and other net expenses primarily associated with restructuring actions, certain litigation and acquisitions.

 

2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $2.081 billion, or $1.16 per share, for intangible amortization expense, impairment charges and other net expense primarily associated with acquisitions, restructuring actions and income from a litigation settlement.

 

12

 

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations 

Fourth Quarter Ended December 31, 2021 and 2020 

(in millions, except per share data) 

(unaudited)

 

   4Q21 
    As
Reported
(GAAP)		   Specified
Items		   As
Adjusted		   % to
Sales		 
Intangible Amortization  $514   $(514)  $--      
Gross Margin   6,188    434    6,622    57.7%
R&D   762    (39)   723    6.3%
SG&A   3,048    (43)   3,005    26.2%
Other (income) expense, net   (63)   (5)   (68)     
Earnings from Continuing Operations before taxes   2,327    521    2,848      
Tax expense on Earnings from Continuing Operations   338    144    482      
Earnings from Continuing Operations   1,989    377    2,366      
Diluted Earnings per Share from Continuing Operations  $1.11   $0.21   $1.32      

 

Specified items reflect intangible amortization expense of $514 million and other net expenses of $7 million that includes costs associated with acquisitions and other expenses, partially offset by a change in estimate to the restructuring actions recognized in the second quarter. See page 16 for additional details regarding specified items.

 

   4Q20 
   As
Reported
(GAAP)		   Specified
Items		   As
Adjusted		   % to
Sales		 
Intangible Amortization  $508   $(508)  $--      
Gross Margin   5,700    557    6,257    58.5%
R&D   698    (61)   637    6.0%
SG&A   2,570    (56)   2,514    23.5%
Other (income) expense, net   (78)   23    (55)     
Earnings from Continuing Operations before taxes   2,388    651    3,039      
Tax expense on Earnings from Continuing Operations   230    197    427      
Earnings from Continuing Operations   2,158    454    2,612      
Diluted Earnings per Share from Continuing Operations  $1.20   $0.25   $1.45      

 

Specified items reflect intangible amortization expense of $508 million and other net expenses of $143 million, primarily associated with acquisitions, restructuring actions and other expenses. See page 17 for additional details regarding specified items.

 

13

 

 

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information From Continuing Operations

Year Ended December 31, 2021 and 2020

(in millions, except per share data)

(unaudited)

 

   12M21 
   As
Reported
(GAAP)		   Specified
Items		   As
Adjusted		   % to
Sales		 
Intangible Amortization  $2,047   $(2,047)  $--      
Gross Margin   22,491    2,476    24,967    58.0%
R&D   2,742    (106)   2,636    6.1%
SG&A   11,324    (317)   11,007    25.6%
Other (income) expense, net   (277)   25    (252)     
Earnings from Continuing Operations before taxes   8,211    2,874    11,085      
Tax expense on Earnings from Continuing Operations   1,140    578    1,718      
Earnings from Continuing Operations   7,071    2,296    9,367      
Diluted Earnings per Share from Continuing Operations  $3.94   $1.27   $5.21      

 

Specified items reflect intangible amortization expense of $2.047 billion and other net expenses of $827 million, primarily associated with restructuring actions, certain litigation, acquisitions and other expenses. See page 18 for additional details regarding specified items.

 

   12M20 
   As
Reported
(GAAP)		   Specified
Items		   As
Adjusted		   % to
Sales		 
Intangible Amortization  $2,132   $(2,132)  $--      
Gross Margin   17,473    2,452    19,925    57.6%
R&D   2,420    (125)   2,295    6.6%
SG&A   9,696    (75)   9,621    27.8%
Other (income) expense, net   (103)   (88)   (191)     
Earnings from Continuing Operations before taxes   4,968    2,740    7,708      
Tax expense on Earnings from Continuing Operations   497    659    1,156      
Earnings from Continuing Operations   4,471    2,081    6,552      
Diluted Earnings per Share from Continuing Operations  $2.49   $1.16   $3.65      

 

Specified items reflect intangible amortization expense of $2.132 billion and other net expenses of $608 million, primarily associated with acquisitions, restructuring actions, asset impairments, and other expenses and litigation settlement income. See page 19 for additional details regarding specified items.

 

14

 

 

A reconciliation of the fourth-quarter tax rates for continuing operations for 2021 and 2020 is shown below:

 

    4Q21     
($ in millions)   Pre-Tax
Income		    Taxes on
Earnings		   Tax
Rate		    
As reported (GAAP)  $2,327   $338   14.5%  1)
Specified items   521    144         
Excluding specified items  $2,848   $482   16.9%   

 

    4Q20     
($ in millions)   Pre-Tax
Income		    Taxes on
Earnings		   Tax
Rate		    
As reported (GAAP)  $2,388   $230   9.6%  2)
Specified items   651    197         
Excluding specified items  $3,039   $427   14.1%   

 

1)2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $40 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $45 million in excess tax benefits associated with share-based compensation.

 

2)2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $135 million of tax benefits related to the impairment of certain assets, approximately $25 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $10 million in excess tax benefits associated with share-based compensation.

 

A reconciliation of the year-to-date tax rates for continuing operations for 2021 and 2020 is shown below:

 

    12M21     
($ in millions)   Pre-Tax
Income		    Taxes on
Earnings		   Tax
Rate		    
As reported (GAAP)  $8,211   $1,140   13.9%  3)
Specified items   2,874    578         
Excluding specified items  $11,085   $1,718   15.5%   
                   

 

    12M20     
($ in millions)   Pre-Tax
Income		    Taxes on
Earnings		   Tax
Rate		    
As reported (GAAP)  $4,968   $497   10.0%  4)
Specified items   2,740    659         
Excluding specified items  $7,708   $1,156   15.0%   

 

3)2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $55 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $145 million in excess tax benefits associated with share-based compensation.

 

4)2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately $170 million of tax benefits related to the impairment of certain assets, approximately $140 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $100 million in excess tax benefits associated with share-based compensation.

  

15

 

 

Abbott Laboratories and Subsidiaries 

Details of Specified Items 

Fourth Quarter Ended December 31, 2021 

(in millions, except per share data) 

(unaudited)

 

   Acquisition or
Divestiture-
related (a)		   Restructuring
and Cost
Reduction
Initiatives (b)		   Intangible
Amortization		   Other (c)   Total
Specifieds		 
Gross Margin  $26   $(110)  $514   $4   $434 
R&D   (6)   (8)   --    (25)   (39)
SG&A   (12)   (23)   --    (8)   (43)
Other (income) expense, net   (2)   --    --    (3)   (5)
Earnings from Continuing Operations before taxes  $46   $(79)  $514   $40    521 
Tax expense on Earnings from Continuing Operations (d)                       144 
Earnings from Continuing Operations                      $377 
Diluted Earnings per Share from Continuing Operations                      $0.21 

 

The table above provides additional details regarding the specified items described on page 13.

 

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes a credit associated with a change in estimate to the charges taken in the second quarter for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.

 

c)Other includes incremental costs to comply with the European Union's Medical Device (MDR) and In Vitro Diagnostics Medical Device (IVDR) Regulations for previously approved products.

 

d)Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

16

 

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Fourth Quarter Ended December 31, 2020 

(in millions, except per share data) 

(unaudited)

 

   Acquisition or
Divestiture-
related (a)		   Restructuring
and Cost
Reduction
Initiatives (b)		   Intangible
Amortization		   Other (c)   Total
Specifieds		 
Gross Margin  $23   $23   $508   $3   $557 
R&D   (2)   6    --    (65)   (61)
SG&A   (25)   (4)   --    (27)   (56)
Other (income) expense, net   24    --    --    (1)   23 
Earnings from Continuing Operations before taxes  $26   $21   $508   $96    651 
Tax expense on Earnings from Continuing Operations (d)                       197 
Earnings from Continuing Operations                      $454 
Diluted Earnings per Share from Continuing Operations                      $0.25 

 

The table above provides additional details regarding the specified items described on page 13.

 

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention and the integration of systems, processes and business activities.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

 

c)Other primarily relates to the impairment of an intangible asset and the net costs related to certain litigation.

 

d)Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

17

 

 

Abbott Laboratories and Subsidiaries

Details of Specified Items

Year Ended December 31, 2021 

(in millions, except per share data) 

(unaudited)

 

   Acquisition or
Divestiture-
related (a)		   Restructuring
and Cost
Reduction
Initiatives (b)		   Intangible
Amortization		   Other (c)   Total
Specifieds		 
Gross Margin  $82   $323   $2,047   $24   $2,476 
R&D   (15)   (7)   --    (84)   (106)
SG&A   (55)   (45)   --    (217)   (317)
Other (income) expense, net   1    1    --    23    25 
Earnings from Continuing Operations before taxes  $151   $374   $2,047   $302    2,874 
Tax expense on Earnings from Continuing Operations (d)                       578 
Earnings from Continuing Operations                      $2,296 
Diluted Earnings per Share from Continuing Operations                      $1.27 

 

The table above provides additional details regarding the specified items described on page 14.

 

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes charges associated with a restructuring plan to align Abbott's manufacturing network for COVID-19 diagnostic tests with changes during the year in current and projected testing demand.

 

c)Other primarily relates to the costs related to certain litigation, incremental costs to comply with MDR and IVDR Regulations for previously approved products, the acquisition of a research and development asset, the impairments of an equity investment and an intangible asset, and the gain on the disposition of an equity method investment.

 

d)Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

 

18

 

 

Abbott Laboratories and Subsidiaries 

Details of Specified Items 

Year Ended December 31, 2020 

(in millions, except per share data) 

(unaudited)

 

   Acquisition or
Divestiture-
related (a)		   Restructuring
and Cost
Reduction
Initiatives (b)		   Intangible
Amortization		   Other (c)   Total
Specifieds		 
Gross Margin  $84   $80   $2,132   $156   $2,452 
R&D   (10)   (3)   --    (112)   (125)
SG&A   (108)   (40)   --    73    (75)
Other (income) expense, net   21    --    --    (109)   (88)
Earnings from Continuing Operations before taxes  $181   $123   $2,132   $304    2,740 
Tax expense on Earnings from Continuing Operations (d)                       659 
Earnings from Continuing Operations                      $2,081 
Diluted Earnings per Share from Continuing Operations                      $1.16 

 

The table above provides additional details regarding the specified items described on page 14.

 

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention, severance, and the integration of systems, processes and business activities.

 

b)Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.

 

c)Other primarily relates to impairment charges related to certain assets and the costs to acquire R&D assets, partially offset by income from the settlement of litigation.

 

d)Reflects the net tax benefit associated with the specified items, the resolution of prior years' tax positions and excess tax benefits associated with share-based compensation.

 

###

 

19

 EX-101.SCH 3 abt-20220126.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 abt-20220126_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 abt-20220126_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Entity Listings, Exchange [Axis] CHICAGO STOCK EXCHANGE, INC [Member] NEW YORK STOCK EXCHANGE, INC. [Member] Entity Listings [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 abt-20220126_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm224433d1_ex99-1sp01img01.jpg GRAPHIC begin 644 tm224433d1_ex99-1sp01img01.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 26, 2022
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 26, 2022
Entity File Number 1-2189
Entity Registrant Name ABBOTT LABORATORIES
Entity Central Index Key 0000001800
Entity Tax Identification Number 36-0698440
Entity Incorporation, State or Country Code IL
Entity Address, Address Line One 100 Abbott Park Road
Entity Address, City or Town Abbott Park
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 224
Local Phone Number 667-6100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member] | CHICAGO STOCK EXCHANGE, INC [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name CHX
Common Stock [Member] | NEW YORK STOCK EXCHANGE, INC. [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name NYSE
XML 9 tm224433d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000001800 2022-01-26 2022-01-26 0000001800 us-gaap:CommonStockMember exch:XCHI 2022-01-26 2022-01-26 0000001800 us-gaap:CommonStockMember exch:XNYS 2022-01-26 2022-01-26 iso4217:USD shares iso4217:USD shares 0000001800 false Common Shares, Without Par Value ABT 8-K 2022-01-26 ABBOTT LABORATORIES IL 1-2189 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 false false false false Common Shares, Without Par Value ABT NYSE CHX false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 3 122 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abbott.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm224433d1_8k.htm abt-20220126.xsd abt-20220126_def.xml abt-20220126_lab.xml abt-20220126_pre.xml tm224433d1_ex99-1.htm http://xbrl.sec.gov/exch/2021 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm224433d1_8k.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 3, "dts": { "definitionLink": { "local": [ "abt-20220126_def.xml" ] }, "inline": { "local": [ "tm224433d1_8k.htm" ] }, "labelLink": { "local": [ "abt-20220126_lab.xml" ] }, "presentationLink": { "local": [ "abt-20220126_pre.xml" ] }, "schema": { "local": [ "abt-20220126.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 68, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 0, "memberStandard": 3, "nsprefix": "abt", "nsuri": "http://abbott.com/20220126", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm224433d1_8k.htm", "contextRef": "From2022-01-26to2022-01-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://abbott.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm224433d1_8k.htm", "contextRef": "From2022-01-26to2022-01-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingsExchangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Listings, Exchange [Axis]" } } }, "localname": "EntityListingsExchangeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_ExchangeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "localname": "ExchangeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "booleanItemType" }, "exch_XCHI": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHICAGO STOCK EXCHANGE, INC [Member]" } } }, "localname": "XCHI", "nsuri": "http://xbrl.sec.gov/exch/2021", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "exch_XNYS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "localname": "XNYS", "nsuri": "http://xbrl.sec.gov/exch/2021", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://abbott.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001104659-22-007648-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-007648-xbrl.zip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end